A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of ISIS 301012 Administration in High Risk Statin Intolerant Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of ISIS 301012 Administration in High Risk Statin Intolerant Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Coronary artery disease; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Lipid metabolism disorders; Metabolic disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASSIST
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2012 Planned number of patients changed from 33 to 50 as reported by European Clinical Trials Database record.
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top